共 50 条
Interferon-Gamma Release Assays
被引:17
|作者:
Belknap, Robert
[1
]
Daley, Charles L.
[2
]
机构:
[1] Univ Colorado, Sch Med, Denver Publ Hlth Dept, Denver, CO 80204 USA
[2] Univ Colorado, Sch Med, Natl Jewish Hlth, Denver, CO 80206 USA
关键词:
Latent tuberculosis infection;
Interferon-gamma release assays;
Tuberculosis;
Tuberculin skin test;
QuantiFERON;
T-SPOT;
LATENT TUBERCULOSIS INFECTION;
QUANTIFERON-TB-GOLD;
HEALTH-CARE WORKERS;
SKIN-TEST;
UNITED-STATES;
IMMUNOCOMPROMISED PATIENTS;
ACTIVE TUBERCULOSIS;
PREDICTIVE-VALUE;
DIAGNOSIS;
DISEASE;
D O I:
10.1016/j.cll.2014.02.007
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
1001 ;
摘要:
Diagnosis of latent tuberculosis infection (LTBI) should be targeted toward individuals and groups with high risk of progression to active tuberculosis (TB). Low-risk populations should not be screened. Interferon-gamma release assays (IGRAs) perform as well or better than the tuberculin skin test in most targeted populations. IGRAs are preferred for bacille Calmette-Guerin (BCG)-vaccinated populations. A positive IGRA in a person at low risk for TB exposure should be confirmed with a repeat test or another method before recommending LTBI treatment. The choice of which IGRA to use is generally based on the costs and feasibility of performing the test.
引用
收藏
页码:337 / +
页数:14
相关论文